_version_ 1868266122559619072
author Raj, Dominic S
Gao, Bei
Sohn, Michael B
Brydges, Christopher
Srivastava, Anvesha
Rabb, Hamid
Cheung, Alfred K
Fiehn, Oliver
Kendrick, Cynthia
Gassman, Jennifer J
Tariq, Anam
Isakova, Tamara
Fried, Linda F
Wolf, Myles
Raphael, Kalani L
Middleton, John P
Abdalla, Yoosif
author_facet Raj, Dominic S
Gao, Bei
Sohn, Michael B
Brydges, Christopher
Srivastava, Anvesha
Rabb, Hamid
Cheung, Alfred K
Fiehn, Oliver
Kendrick, Cynthia
Gassman, Jennifer J
Tariq, Anam
Isakova, Tamara
Fried, Linda F
Wolf, Myles
Raphael, Kalani L
Middleton, John P
Abdalla, Yoosif
Raj, Dominic S
Gao, Bei
Sohn, Michael B
Brydges, Christopher
Srivastava, Anvesha
Rabb, Hamid
Cheung, Alfred K
Fiehn, Oliver
Kendrick, Cynthia
Gassman, Jennifer J
Tariq, Anam
Isakova, Tamara
Fried, Linda F
Wolf, Myles
Raphael, Kalani L
Middleton, John P
Abdalla, Yoosif
collection PubMed - marine biology
contents Prebiotic Administration to Chronic Kidney Disease Patients Modifies Their Fecal Microbiome and Host Metabolism. Raj, Dominic S Gao, Bei Sohn, Michael B Brydges, Christopher Srivastava, Anvesha Rabb, Hamid Cheung, Alfred K Fiehn, Oliver Kendrick, Cynthia Gassman, Jennifer J Tariq, Anam Isakova, Tamara Fried, Linda F Wolf, Myles Raphael, Kalani L Middleton, John P Abdalla, Yoosif Aged Female Humans Male Middle Aged Amino Acids Dysbiosis Feces Gastrointestinal Microbiome Inulin Oligosaccharides Pilot Projects Prebiotics Renal Insufficiency, Chronic Prebiotics are believed to improve gut microbial dysbiosis and dysmetabolism in chronic kidney disease (CKD) patients. However, impact of prebiotics on gut microbial metagenome and dynamic changes in metabolome has not been clearly defined. We conducted a nonrandomized, open-label, three-phase pilot trial to investigate the effect of daily oral prebiotic, oligofructose-enriched inulin (p-inulin), on stool functional metagenome and changes in plasma, urine, and stool metabolites in 13 CKD patients. The study comprised a pretreatment phase (8 weeks), p-inulin treatment phase (12 weeks), and post-treatment phase (8 weeks). During treatment phase, there was a significant increase in the abundance of Bifidobacterium adolescentis, Bifidobacterium longum, and Lachnospiraceae species. Microbial pathways related to carbohydrate degradation and amino acid biosynthesis were enriched during the treatment phase, but urea biosynthetic pathway was attenuated. In plasma, metabolic biosynthetic pathways for valine, leucine, and isoleucine were activated during the treatment phase. Microbial genes related to lipid metabolism were enriched during post-treatment. Abundance of several polar and nonpolar lipids were altered in plasma and stool samples during treatment and post-treatment phases. Pathway analysis for lipids indicated suppression of triglyceride biosynthesis in plasma and enhanced triglyceride degradation in stool during the treatment phase. Secondary bile acid levels in plasma, urine, and stool were significantly reduced during p-inulin consumption. Urine levels of indoxyl sulfate and p-cresol sulfate were reduced during treatment phase. P-inulin administration to CKD patients resulted in a distinct shift in toxin-generating proteolysis to amino acid biosynthesis and favorable changes in lipid metabolism.
format Artículo científico
id pubmed_41275986
institution PubMed
language en
publishDate 2026
publisher Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
record_format pubmed
spellingShingle Prebiotic Administration to Chronic Kidney Disease Patients Modifies Their Fecal Microbiome and Host Metabolism.
Raj, Dominic S
Gao, Bei
Sohn, Michael B
Brydges, Christopher
Srivastava, Anvesha
Rabb, Hamid
Cheung, Alfred K
Fiehn, Oliver
Kendrick, Cynthia
Gassman, Jennifer J
Tariq, Anam
Isakova, Tamara
Fried, Linda F
Wolf, Myles
Raphael, Kalani L
Middleton, John P
Abdalla, Yoosif
Aged
Female
Humans
Male
Middle Aged
Amino Acids
Dysbiosis
Feces
Gastrointestinal Microbiome
Inulin
Oligosaccharides
Pilot Projects
Prebiotics
Renal Insufficiency, Chronic
Prebiotic Administration to Chronic Kidney Disease Patients Modifies Their Fecal Microbiome and Host Metabolism. Raj, Dominic S Gao, Bei Sohn, Michael B Brydges, Christopher Srivastava, Anvesha Rabb, Hamid Cheung, Alfred K Fiehn, Oliver Kendrick, Cynthia Gassman, Jennifer J Tariq, Anam Isakova, Tamara Fried, Linda F Wolf, Myles Raphael, Kalani L Middleton, John P Abdalla, Yoosif Aged Female Humans Male Middle Aged Amino Acids Dysbiosis Feces Gastrointestinal Microbiome Inulin Oligosaccharides Pilot Projects Prebiotics Renal Insufficiency, Chronic Prebiotics are believed to improve gut microbial dysbiosis and dysmetabolism in chronic kidney disease (CKD) patients. However, impact of prebiotics on gut microbial metagenome and dynamic changes in metabolome has not been clearly defined. We conducted a nonrandomized, open-label, three-phase pilot trial to investigate the effect of daily oral prebiotic, oligofructose-enriched inulin (p-inulin), on stool functional metagenome and changes in plasma, urine, and stool metabolites in 13 CKD patients. The study comprised a pretreatment phase (8 weeks), p-inulin treatment phase (12 weeks), and post-treatment phase (8 weeks). During treatment phase, there was a significant increase in the abundance of Bifidobacterium adolescentis, Bifidobacterium longum, and Lachnospiraceae species. Microbial pathways related to carbohydrate degradation and amino acid biosynthesis were enriched during the treatment phase, but urea biosynthetic pathway was attenuated. In plasma, metabolic biosynthetic pathways for valine, leucine, and isoleucine were activated during the treatment phase. Microbial genes related to lipid metabolism were enriched during post-treatment. Abundance of several polar and nonpolar lipids were altered in plasma and stool samples during treatment and post-treatment phases. Pathway analysis for lipids indicated suppression of triglyceride biosynthesis in plasma and enhanced triglyceride degradation in stool during the treatment phase. Secondary bile acid levels in plasma, urine, and stool were significantly reduced during p-inulin consumption. Urine levels of indoxyl sulfate and p-cresol sulfate were reduced during treatment phase. P-inulin administration to CKD patients resulted in a distinct shift in toxin-generating proteolysis to amino acid biosynthesis and favorable changes in lipid metabolism.
title Prebiotic Administration to Chronic Kidney Disease Patients Modifies Their Fecal Microbiome and Host Metabolism.
topic Aged
Female
Humans
Male
Middle Aged
Amino Acids
Dysbiosis
Feces
Gastrointestinal Microbiome
Inulin
Oligosaccharides
Pilot Projects
Prebiotics
Renal Insufficiency, Chronic
url https://pubmed.ncbi.nlm.nih.gov/41275986/